Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

May 12, 2023 | Press Releases

CUPERTINO, Calif., May 12, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data

May 11, 2023 | Press Releases

Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model IND submission for brilaroxazine lipogel in psoriasis expected in 2024 Reviva has filed composition of matter...

Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023

May 4, 2023 | Press Releases

CUPERTINO, Calif., May 04, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives

May 1, 2023 | Press Releases

Multifaceted activity of brilaroxazine supports potential for improvement in behavioral symptoms as well as accompanying neuroinflammation This proof-of-concept data supported the initial clinical development of brilaroxazine and reinforces the clinical profile...

Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia

Apr 25, 2023 | Press Releases

Virtual event on Tuesday, May 2, 2023 at 11:00am ET will feature key opinion leader (KOL) Larry Ereshefsky, PharmD, BCPP, FCCP, Chief Scientific Officer, Follow the MoleculeCUPERTINO, Calif., April 25, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH)...

Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry

Apr 20, 2023 | Press Releases

CUPERTINO, Calif., April 20, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...